Literature DB >> 28611130

Precision Medicine for Heart Failure: Lessons From Oncology.

Arthur M Feldman1, Christopher D Kontos2, Joseph M McClung2, Glenn S Gerhard2, Kamel Khalili2, Joseph Y Cheung2.   

Abstract

Entities:  

Keywords:  National Institutes of Health (U.S.); cardiovascular disease; genetics; heart failure; precision medicine

Mesh：

Substances：

Year:  2017        PMID： 28611130      PMCID： PMC5643024          DOI： 10.1161/CIRCHEARTFAILURE.117.004202

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN： 1941-3289            Impact factor:   8.790


× No keyword cloud information.
  28 in total

Review 1.  Breaking BAG: The Co-Chaperone BAG3 in Health and Disease.

Authors:  Christian Behl
Journal:  Trends Pharmacol Sci       Date:  2016-05-06       Impact factor: 14.819

2.  The Shared Health Research Information Network (SHRINE): a prototype federated query tool for clinical data repositories.

Authors:  Griffin M Weber; Shawn N Murphy; Andrew J McMurry; Douglas Macfadden; Daniel J Nigrin; Susanne Churchill; Isaac S Kohane
Journal:  J Am Med Inform Assoc       Date:  2009-06-30       Impact factor: 4.497

3.  A new initiative on precision medicine.

Authors:  Francis S Collins; Harold Varmus
Journal:  N Engl J Med       Date:  2015-01-30       Impact factor: 91.245

4.  Limits to Personalized Cancer Medicine.

Authors:  Ian F Tannock; John A Hickman
Journal:  N Engl J Med       Date:  2016-09-29       Impact factor: 91.245

5.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

6.  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Authors:  Meletios A Dimopoulos; Philippe Moreau; Antonio Palumbo; Douglas Joshua; Ludek Pour; Roman Hájek; Thierry Facon; Heinz Ludwig; Albert Oriol; Hartmut Goldschmidt; Laura Rosiñol; Jan Straub; Aleksandr Suvorov; Carla Araujo; Elena Rimashevskaya; Tomas Pika; Gianluca Gaidano; Katja Weisel; Vesselina Goranova-Marinova; Anthony Schwarer; Leonard Minuk; Tamás Masszi; Ievgenii Karamanesht; Massimo Offidani; Vania Hungria; Andrew Spencer; Robert Z Orlowski; Heidi H Gillenwater; Nehal Mohamed; Shibao Feng; Wee-Joo Chng
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316

7.  G-protein beta-3 subunit genotype predicts enhanced benefit of fixed-dose isosorbide dinitrate and hydralazine: results of A-HeFT.

Authors:  Dennis M McNamara; Anne L Taylor; S William Tam; Manuel Worcel; Clyde W Yancy; Karen Hanley-Yanez; Jay N Cohn; Arthur M Feldman
Journal:  JACC Heart Fail       Date:  2014-10-08       Impact factor: 12.035

Review 8.  Intratumor heterogeneity: evolution through space and time.

Authors:  Charles Swanton
Journal:  Cancer Res       Date:  2012-09-20       Impact factor: 12.701

Review 9.  Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.

Authors:  Raghav Sundar; Maxime Chénard-Poirier; Dearbhaile Catherine Collins; Timothy A Yap
Journal:  Front Med (Lausanne)       Date:  2017-04-10

10.  First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

Authors:  J-Y Douillard; G Ostoros; M Cobo; T Ciuleanu; R McCormack; A Webster; T Milenkova
Journal:  Br J Cancer       Date:  2013-11-21       Impact factor: 7.640
View more
  2 in total

1.  A common variant of RIP3 promoter region is associated with poor prognosis in heart failure patients by influencing SOX17 binding.

Authors:  Dong Hu; Jin Huang; Senlin Hu; Ying Zhang; Shiyang Li; Yang Sun; Chenze Li; Guanglin Cui; Dao Wen Wang
Journal:  J Cell Mol Med       Date:  2019-05-31       Impact factor: 5.310

Review 2.  Kidney disease trials for the 21st century: innovations in design and conduct.

Authors:  William G Herrington; Natalie Staplin; Richard Haynes
Journal:  Nat Rev Nephrol       Date:  2019-10-31       Impact factor: 28.314
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.